In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea.
The in vitro activity of rifaximin against 84 diarrheagenic Escherichia coli and 11 Shigella sonnei causing traveler's diarrhea was evaluated. The MIC of rifaximin ranged between <0.007 and 32 mg/L; other agents tested had an MIC of >256 mg/L in most cases. The results showed the potential use of rifaximin to treat these infections.
Ruiz
Joaquim
J
Hospital Clinic, Centro de Salud Internacional (CRESIB); IDIBAPS, Universitat de Barcelona, 08036-Barcelona, Spain. joruiz@clinic.ub.es
Mensa
Laura
L
O'Callaghan
Cristina
C
Pons
Maria J
MJ
González
Ana
A
Vila
Jordi
J
Gascón
Joaquim
J
D000890:Anti-Infective Agents / Q000494:pharmacology*; D003967:Diarrhea / Q000382:microbiology*; D024881:Drug Resistance, Bacterial; D054307:Enterotoxigenic Escherichia coli / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008826:Microbial Sensitivity Tests; D012294:Rifamycins / Q000494:pharmacology*; D000078262:Rifaximin; D012764:Shigella sonnei / Q000187:drug effects* / Q000302:isolation & purification; D014195:Travel
D000890:Anti-Infective Agents; D012294:Rifamycins; D000078262:Rifaximin